Armin Kuellmer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Armin Kuellmer has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Arthur Schmidt
Bosch Health Campus, Robert Bosch Hospital, BW, Germany
3 shared publications- Julius Mueller
University of Freiburg Faculty of Medicine, BW, Germany
2 shared publications Robert Thimme
University of Freiburg Faculty of Medicine, BW, Germany
2 shared publications- Adhara Lazaro
Department of Medicine, Institute of Exercise and Occupational Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany
1 shared publication Andreas Wannhoff
Department of Medicine I, Klinikum Ludwigsburg, Ludwigsburg, Germany
1 shared publication- Annette Schmitt-Graeff
Faculty of Medicine, Medical Center, University of Freiburg, 79106 Freiburg, Germany
1 shared publication
Latest Publications
- Open Access
- 13 January 2026
- Published by Georg Thieme Verlag KG in Endoscopy International Open
- Vol. 14 (CP)
A New Endoscopic Device to Facilitate APC Treatment: First Multicenter Clinical Experience
Background and Study Aims Argon plasma coagulation (APC) is an established ablation technique, but limited by tangential probe orientation. ArgoCap was developed to allow precise, safe, and reproducible APC through visualizing the argon beam, shielding the probe, maintaining a defined distance, and enabling hybrid APC procedures. This study aimed to evaluate the clinical feasibility and safety of ArgoCap across multiple indications. Patients and Methods Between January 2022 and May 2025, 54 APC procedures using the ArgoCap were performed at three expert centers. Indications included Barrett’s mucosa, ectopic gastric mucosa, gastric angioectasia, gastric antral vascular ectasia, radiation proctitis, and other indications. Primary endpoint was technical success, defined as access to the lesions and macroscopically complete ablation. Secondary endpoints included technical complications, adverse events, and procedural time. Results The majority of lesions were located in the esophagus (70%), followed by stomach (19%) and rectum (11%). Median lesion size was 13 mm (range 2–240 mm). Median ablation and procedure times were 8 min (2–15 min) and 25 min (8–75 min), respectively. Technical success was achieved in 47 cases (87%); subtotal ablation (>90% of the lesion) was possible in 52 cases (96%). Technical difficulties occurred in 1 case (2%); primary complication (ulceration with subsequent bleeding) was observed in 1 case (2%). Conclusions The ArgoCap enables easy and precise APC in the upper and lower gastrointestinal tract across multiple indications. It facilitates lesion access and visualization, reduces unintended mucosal contact, and allows hybrid APC procedures.
- 13 January 2026
- Published by Georg Thieme Verlag KG in Endoscopy International Open
- Vol. 14 (CP)
Open AccessA New Endoscopic Device to Facilitate APC Treatment: First Multicenter Clinical Experience
Background and Study Aims Argon plasma coagulation (APC) is an established ablation technique, but limited by tangential probe orientation. ArgoCap was developed to allow precise, safe, and reproducible APC through visualizing the argon beam, shielding the probe, maintaining a defined distance, and enabling hybrid APC procedures. This study aimed to evaluate the clinical feasibility and safety of ArgoCap across multiple indications. Patients and Methods Between January 2022 and May 2025, 54 APC procedures using the ArgoCap were performed at three expert centers. Indications included Barrett’s mucosa, ectopic gastric mucosa, gastric angioectasia, gastric antral vascular ectasia, radiation proctitis, and other indications. Primary endpoint was technical success, defined as access to the lesions and macroscopically complete ablation. Secondary endpoints included technical complications, adverse events, and procedural time. Results The majority of lesions were located in the esophagus (70%), followed by stomach (19%) and rectum (11%). Median lesion size was 13 mm (range 2–240 mm). Median ablation and procedure times were 8 min (2–15 min) and 25 min (8–75 min), respectively. Technical success was achieved in 47 cases (87%); subtotal ablation (>90% of the lesion) was possible in 52 cases (96%). Technical difficulties occurred in 1 case (2%); primary complication (ulceration with subsequent bleeding) was observed in 1 case (2%). Conclusions The ArgoCap enables easy and precise APC in the upper and lower gastrointestinal tract across multiple indications. It facilitates lesion access and visualization, reduces unintended mucosal contact, and allows hybrid APC procedures.
- Open Access
- 13 January 2026
- Published by Georg Thieme Verlag KG in Endoscopy International Open
- Vol. 14 (CP)
Clip-Based Endoscopic Anastomotic Reduction in Patients with Dumping Syndrome and Postbariatric Hypoglycemia after Roux-en-Y Gastric Bypass
Background and Aims Dumping syndrome (DS) and postbariatric hypoglycemia (PBH) represent common complications after Roux-en-Y gastric bypass (RYGB). Transoral outlet reduction (TORe) addresses the rapid passage of food through the gastrojejunal anastomosis which is central in pathophysiology. In this prospective multicenter study, technical feasibility and short-term clinical efficacy of a new clip-based endoscopic system (BARS) were evaluated. Methods Twenty-three consecutive patients at three centers in Germany were included. The primary endpoint was feasibility measured as reduction of anastomotic diameter and surface. Secondary endpoints included changes of the Dumping symptom score and glycaemia in modified oral glucose tolerance tests (mod. oGTT), anastomotic diameter, quality of life after 12 weeks and adverse events. Results The procedure was technically feasable in all cases. Median anastomotic diameter was reduced from 40 mm (IQR: 30–50) to 9 mm (IQR: 7–10); −77%) at baseline (p < 0.001). At week 12, median Sigstad-Score decreased from 17,5 (IQR: 12.8–21.0) to 5 (IQR: 0–11; p < 0.001). Median anastomotic diameter was still reduced to 20 mm (IQR: 12–30; p = 0.004; −47%). Modified oGTT demonstrated abolished DS in 3 of 23 patients (13%) while no effect was seen in PBH at 12 weeks. Median BMI decreased from 30.6 kg/m2 (IQR: 28–35.6) to 29.25 kg/m2 (IQR: 26.7–33.4; p = 0.001). Quality of life (QoL) improved significantly in five of eight subcategories of the SF-36. Conclusion Clip-based anastomotic reduction for DS and PBH seems feasible, safe and showed significant improvements in Sigstad scores and QoL in short-term analysis.
- 13 January 2026
- Published by Georg Thieme Verlag KG in Endoscopy International Open
- Vol. 14 (CP)
Open AccessClip-Based Endoscopic Anastomotic Reduction in Patients with Dumping Syndrome and Postbariatric Hypoglycemia after Roux-en-Y Gastric Bypass
Background and Aims Dumping syndrome (DS) and postbariatric hypoglycemia (PBH) represent common complications after Roux-en-Y gastric bypass (RYGB). Transoral outlet reduction (TORe) addresses the rapid passage of food through the gastrojejunal anastomosis which is central in pathophysiology. In this prospective multicenter study, technical feasibility and short-term clinical efficacy of a new clip-based endoscopic system (BARS) were evaluated. Methods Twenty-three consecutive patients at three centers in Germany were included. The primary endpoint was feasibility measured as reduction of anastomotic diameter and surface. Secondary endpoints included changes of the Dumping symptom score and glycaemia in modified oral glucose tolerance tests (mod. oGTT), anastomotic diameter, quality of life after 12 weeks and adverse events. Results The procedure was technically feasable in all cases. Median anastomotic diameter was reduced from 40 mm (IQR: 30–50) to 9 mm (IQR: 7–10); −77%) at baseline (p < 0.001). At week 12, median Sigstad-Score decreased from 17,5 (IQR: 12.8–21.0) to 5 (IQR: 0–11; p < 0.001). Median anastomotic diameter was still reduced to 20 mm (IQR: 12–30; p = 0.004; −47%). Modified oGTT demonstrated abolished DS in 3 of 23 patients (13%) while no effect was seen in PBH at 12 weeks. Median BMI decreased from 30.6 kg/m2 (IQR: 28–35.6) to 29.25 kg/m2 (IQR: 26.7–33.4; p = 0.001). Quality of life (QoL) improved significantly in five of eight subcategories of the SF-36. Conclusion Clip-based anastomotic reduction for DS and PBH seems feasible, safe and showed significant improvements in Sigstad scores and QoL in short-term analysis.
- 3 October 2019
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 54 (10) , 1189-1198
Esophageal lichen planus: towards diagnosis of an underdiagnosed disease
Background: Although lichen planus (LP) is a common skin disorder, the prevalence of esophageal involvement (ELP) and its clinical manifestations are poorly defined. We aimed to establish diagnostic criteria and characterize disease outcomes of ELP. Methods: Clinical, endoscopic, histological, and immunofluorescence data from consecutive patients with known LP between 2013 and 2018 were analyzed. We established endoscopic (denudation and tearing of the mucosa, hyperkeratosis and trachealization) and histological criteria (mucosal detachment, T-lymphocytic infiltrate, intraepithelial apoptosis, dyskeratosis, and fibrinogen deposits along the basement membrane) to grade disease severity. Endoscopic findings were correlated with clinical symptoms. Response to medical therapy was monitored. Results: Fifty-two consecutive patients (median age 59.5 years) were analyzed. According to our grading system, 16 patients were considered as severe and 18 as mild ELP. Dysphagia was the only symptom which differentiated patients with severe (14/16) or mild ELP (8/18) from patients without ELP (1/18). Concomitant oral and genital involvement of LP was associated with the presence of ELP, while oral involvement alone was not. Follow-up of 14/16 patients with severe EPL for at least one year revealed that most of these patients responded to topical corticosteroids (budesonide: n = 9/10 or fluticasone n = 2/2). Three budesonide patients experienced a resolution of symptomatic esophageal stenosis. Conclusions: Esophageal involvement of LP is frequent, but may be asymptomatic. ELP can be diagnosed using the diagnostic criteria proposed here. Dysphagia and combined oral and genital manifestation are associated with ELP. Therapy with topical corticosteroids appears to be a prudent therapeutic approach for ELP.
- 3 October 2019
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 54 (10) , 1189-1198
Esophageal lichen planus: towards diagnosis of an underdiagnosed disease
Background: Although lichen planus (LP) is a common skin disorder, the prevalence of esophageal involvement (ELP) and its clinical manifestations are poorly defined. We aimed to establish diagnostic criteria and characterize disease outcomes of ELP. Methods: Clinical, endoscopic, histological, and immunofluorescence data from consecutive patients with known LP between 2013 and 2018 were analyzed. We established endoscopic (denudation and tearing of the mucosa, hyperkeratosis and trachealization) and histological criteria (mucosal detachment, T-lymphocytic infiltrate, intraepithelial apoptosis, dyskeratosis, and fibrinogen deposits along the basement membrane) to grade disease severity. Endoscopic findings were correlated with clinical symptoms. Response to medical therapy was monitored. Results: Fifty-two consecutive patients (median age 59.5 years) were analyzed. According to our grading system, 16 patients were considered as severe and 18 as mild ELP. Dysphagia was the only symptom which differentiated patients with severe (14/16) or mild ELP (8/18) from patients without ELP (1/18). Concomitant oral and genital involvement of LP was associated with the presence of ELP, while oral involvement alone was not. Follow-up of 14/16 patients with severe EPL for at least one year revealed that most of these patients responded to topical corticosteroids (budesonide: n = 9/10 or fluticasone n = 2/2). Three budesonide patients experienced a resolution of symptomatic esophageal stenosis. Conclusions: Esophageal involvement of LP is frequent, but may be asymptomatic. ELP can be diagnosed using the diagnostic criteria proposed here. Dysphagia and combined oral and genital manifestation are associated with ELP. Therapy with topical corticosteroids appears to be a prudent therapeutic approach for ELP.